肌萎缩侧索硬化中神经丝轻链的生物标志物资格认定:理论与实践
本文通过学术界、产业界和患者倡导团体代表的共识讨论,探讨是否应就神经丝轻链(NfL)在美国食品药品监督管理局(FDA)寻求正式生物标志物资格认定以促进肌萎缩侧索硬化(ALS)疗法开发。讨论认为NfL作为预后、应答和潜在安全性生物标志物已有大量证据支持,且FDA基于NfL降低可能预测临床获益的认可而加速批准了一种降低SOD1的反义寡核苷酸,结论是正式资格认定虽有若干益处但并非NfL持续和未来用于ALS疗法开发的必要条件。
要点
- 大量科学证据支持NfL作为广泛ALS人群的预后、应答和潜在安全性生物标志物。
- NfL可作为SOD1致病性变异携带者亚群的风险/易感性生物标志物。
- FDA基于NfL降低合理可能预测临床获益的认可,加速批准了一种降低SOD1的反义寡核苷酸。
核心结论
- NfL作为预后、应答、风险/易感性和/或安全性生物标志物的效用已被ALS领域广泛接受,正式资格认定虽有若干益处但并非其持续和未来用于ALS疗法开发的必要条件。
- 针对寻求NfL生物标志物资格认定的利弊权衡在不同疾病和使用场景中无疑会有所不同,但已发表数据的稳健性和ALS领域的审慎讨论或可为面临相同问题的其他疾病领域提供有价值的见解。
研究设计与样本
- 学术界、产业界和患者倡导团体代表之间的共识讨论。
主要发现
- 大量科学证据支持NfL作为广泛ALS人群的预后、应答和潜在安全性生物标志物,以及作为SOD1致病性变异携带者亚群的风险/易感性生物标志物。
- NfL尚未就上述任何使用场景获得正式资格认定,但FDA已部分基于NfL降低合理可能预测临床获益的认可,加速批准了一种降低SOD1的反义寡核苷酸。
- NfL越来越多地被纳入ALS疗法开发计划,表明其作为预后、应答、风险/易感性和/或安全性生物标志物的效用已被领域广泛接受。
- FDA愿意在缺乏正式资格认定的情况下基于严格的同行评议数据做出监管决定,使作者得出结论:正式资格认定虽有若干益处但并非必要。
临床怎么用
- NfL已被广泛接受为ALS疗法开发中的预后、应答、风险/易感性和/或安全性生物标志物。
- FDA已基于NfL降低合理可能预测临床获益的认可,加速批准了一种降低SOD1的反义寡核苷酸。
- 作者认为正式资格认定虽有若干益处但并非NfL持续和未来用于ALS疗法开发的必要条件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore whether the utility of neurofilament light chain (NfL), as a biomarker to aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by obtaining formal qualification from the US Food and Drug Administration for a defined context-of-use. METHODS: Consensus discussion among academic, industry, and patient advocacy group representatives. RESULTS: A wealth of scientific evidence supports the use of NfL as a prognostic, response, and potential safety biomarker in the broad ALS population, and as a risk/susceptibility biomarker among the subset of SOD1 pathogenic variant carriers. Although NfL has not yet been formally qualified for any of these contexts-of-use, the US Food and Drug Administration has provided accelerated approval for an SOD1-lowering antisense oligonucleotide, based partially on the recognition that a reduction in NfL is reasonably likely to predict a clinical benefit. INTERPRETATION: The increasing incorporation of NfL into ALS therapy development plans provides evidence that its utility-as a prognostic, response, risk/susceptibility, and/or safety biomarker-is already widely accepted by the community. The willingness of the US Food and Drug Administration to base regulatory decisions on rigorous peer-reviewed data-absent formal qualification, leads us to conclude that formal qualification, despite some benefits, is not essential for ongoing and future use of NfL as a tool to aid ALS therapy development. Although the balance of considerations for and against seeking NfL biomarker qualification will undoubtedly vary across different diseases and contexts-of-use, the robustness of the published data and careful deliberations of the ALS community may offer valuable insights for other disease communities grappling with the same issues. ANN NEUROL 2024;95:211-216.
引用
- Benatar M, Ostrow LW, Lewcock JW, et al. Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice. Ann Neurol. 2023. PMID: 38110839. doi:10.1002/ana.26860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。